YMGE_8September2022

The COVID-19 pandemic has had a profound impact on elective GI endoscopy procedures. Concerning the diagnostic performance of clinical screening for COVID-19 in patients with appointments for outpatient upper GI endoscopy and colonoscopy, using the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) nucleic acid amplification testing (NAAT) as the gold standard, what would you say?

A. Clinical screening has low sensitivity, high specificity, and a high negative predictive value for COVID-19 infection.
B. Clinical screening has high sensitivity, low specificity, and a low negative predictive value for COVID-19 infection.
C. Clinical screening has high sensitivity and specificity for COVID-19 infection, making NAAT optional.
D. Clinical screening has low sensitivity and specificity for COVID-19 infection.